证券代码：600998 证券简称：九州通 公告编号：临 2025-043 本次利润分配方案经九州通医药集团股份有限公司（以下简称"公司"）2025 年 5 月 23 日 的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 九州通医药集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.20元（含税） ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/16 | － | 2025/6/17 | 2025/6/17 | | ? 差异化分红送转： 是 一、 通过分配方案的股东会届次和日期 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，上市 公 ...

Group 1 - The stock price of Haiwang Bio has broken through the top of a six-month trading range, with a cumulative increase of 8.97% over nine trading days, significantly outperforming the industry average of 3.36% [1][2] - The trading volume reached 664.55 million shares, with a total capital inflow of 1.71 billion yuan, indicating a notable increase in trading activity [1][2] Group 2 - Despite facing significant cyclical pressures in recent years, Haiwang Bio's revenue for 2024 is expected to maintain a substantial level of 30.317 billion yuan, driven by strategic adjustments and optimization of low-efficiency subsidiaries [4] - The company anticipates a net loss attributable to shareholders of 1.193 billion yuan for 2024, which represents a significant reduction compared to the previous year's loss of 1.69 billion yuan [4] - The company has been actively reducing goodwill impairment, which is nearing completion, laying a foundation for long-term growth [4] Group 3 - The Chinese pharmaceutical industry is undergoing a critical phase of quality upgrades, with policies accelerating the exit of small distributors, benefiting leading companies like Haiwang Bio [6] - Haiwang Bio is enhancing its competitive edge through a nationwide logistics network and is transitioning from product provision to service solutions, including customized SPD services for medical institutions [6] - The company has received clinical trial approval for its self-developed NEP018 tablet, a small molecule enzyme inhibitor targeting gastrointestinal tumors, which is expected to open a new growth avenue as the market for small molecule anti-tumor drugs is projected to exceed 200 billion yuan by 2030 [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 2025年6月，北京市竞天公诚律师事务所上海分所就南京医药股份有限公司2021年限制性股票激励计划 回购注销部分限制性股票实施情况出具法律意见书。 已履行必要程序并完成信息披露 回购注销具体情况原因及依据：依据《激励计划》，因28名激励对象分别因离职、退休、考核不达标等 不符合激励条件，公司需对其已获授但尚未解除限售的409,626股限制性股票进行回购注销。对象及股 份数量：涉及核心骨干（非董事、高级管理人员）28人，合计拟回购注销限制性股票409,626股，即 40.96万股。注销日期：公司已在中登上海分公司开设回购专用证券账户，并申请办理回购注销手续， 上述限制性股票预计于2025年6月12日完成注销，后续将依法办理股份注销登记等手续。 律师认为，截至法律意见书出具之日，南京医药本次回购注销符合注销条件，涉及对象、股份数量及注 销日期均符合相关规定。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第 ...

回购注销部分限制性股票实施情况 之 北京市竞天公诚律师事务所上海分所 关于 南京医药股份有限公司 法律意见书 上海市徐汇区淮海中路 1010 号嘉华中心 45 层 邮编：200031 Suite 45/F, K.Wah Centre, 1010 Huaihai Road (M), Xuhui District, Shanghai 200031, China 电话/Tel: +86 21 5404 9930 传真/Fax: +86 21 5404 9931 网址/Website: http://www.jingtian.com 二〇二五年六月 北京市竞天公诚律师事务所上海分所 法律意见书 北京市竞天公诚律师事务所上海分所 关于南京医药股份有限公司 回购注销部分限制性股票实施情况之 法律意见书 南京医药股份有限公司： 北京市竞天公诚律师事务所上海分所（以下简称"本所"）依法接受南京医 药股份有限公司（以下简称"南京医药"或"公司"）委托，担任公司 2021 年 限制性股票激励计划（以下简称"本次激励计划"）的专项法律顾问，就本次激 励计划回购注销部分激励对象已获授但尚未解除限售的限制性股票（以下简称 "本次回购注 ...

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. is issuing convertible bonds to unspecified investors, with a total amount of RMB 1,081,491,000, to be used for various investment projects [3][16][24] Group 1: Issuance Details - The company has received approval from its board and regulatory authorities to issue 10,814,910 convertible bonds, each with a face value of RMB 100 [3][4] - The total amount raised from this issuance is RMB 1,069,040,922.31 after deducting issuance costs [3][16] - The bonds will have a maturity period of six years from the date of issuance [5][16] Group 2: Bond Terms - The coupon rates for the bonds are set at 0.20% for the first year and 0.40% for the second year, with further rates to be determined for subsequent years [5][16] - The initial conversion price for the bonds is set at RMB 5.29 per share, subject to adjustments based on specific corporate actions [8][24] - The bonds will be redeemable at 108% of the face value after maturity, and the company has the right to redeem them under certain conditions during the conversion period [9][10] Group 3: Use of Proceeds - The net proceeds from the bond issuance will be allocated to various investment projects totaling RMB 118,665,520, with the company covering any shortfall [16][24] - The company plans to ensure that the timing of fund availability aligns with the project implementation schedule [16] Group 4: Shareholder Rights and Adjustments - Existing shareholders will have preferential rights to subscribe to the bonds based on their holdings as of the record date [14][16] - The company will adjust the conversion price of the bonds in response to stock dividends, capital increases, or other equity changes [8][24] - The company has established a dedicated account for the repurchase of restricted stock as part of its incentive plan, which will not significantly impact the bondholders' rights [19][24]

上交所公开信息显示，当日该股因日振幅值达16.59%上榜，营业部席位合计净卖出38.44万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.71亿元，其中，买入成交额为8547.13 万元，卖出成交额为8585.57万元，合计净卖出38.44万元。 人民同泰(600829)今日下跌4.65%，全天换手率11.24%，成交额5.99亿元，振幅16.59%。龙虎榜数据显 示，营业部席位合计净卖出38.44万元。 具体来看，今日上榜营业部中，第一大买入营业部为国新证券股份有限公司北京中关村大街证券营业 部，买入金额为2592.48万元，第一大卖出营业部为开源证券股份有限公司湖北分公司，卖出金额为 2921.16万元。 | 卖四 | 中泰证券股份有限公司北京朝外大街证券营业部 | 1307.60 | | --- | --- | --- | | 卖五 | 申万宏源证券有限公司上海静安区延长中路证券营业部 | 1130.24 | （文章来源：证券时报网） 4月19日公司发布的一季报数据显示，一季度公司共实现营业收入26.67亿元，同比增长2.65%，实现净 利润4584.09万元，同比下降41.48%。（ ...

中国经济网北京6月9日讯 海王生物（000078）（000078.SZ）6月7日发布关于终止控制权变更及向特定 对象发行股票事项的公告。近日，公司、海王集团及丝纺集团签署了《<关于深圳市海王生物工程股份 有限公司之合作协议书>解除协议》，丝纺集团与海王集团及其一致行动人张思民、张锋、王菲签署了 《<关于深圳市海王生物工程股份有限公司之股份转让协议>及<关于深圳市海王生物工程股份有限公司 之表决权放弃协议>解除协议》，公司本次控制权变更事项终止。 鉴于公司控制权变更事项终止，公司于2025年6月6日召开了2025年第三次独立董事专门会议、第九届董 事局第二十四次会议、第九届监事会第二十次会议，审议通过了终止向特定对象发行A股股票事项的相 关事项，同意终止向特定对象发行A股股票，并签署股份认购协议的解除协议。 海王生物2024年7月30日披露《2024年度向特定对象发行A股股票预案》称，本次向特定对象发行A股股 票的发行对象为丝纺集团及其控股股东广新集团。丝纺集团、广新集团拟以现金方式认购公司本次发行 的全部股票。 丝纺集团取得上市公司控制权后，按照拟发行股数计算，本次发行完成后，丝纺集团及其一致行动人持 有的上 ...

Core Viewpoint - 九州通 is undergoing a strategic transformation towards light asset operations and aims to become a dual-listed company on A-shares and public REITs, enhancing its market position in the biopharmaceutical industry [1][2]. Group 1: Strategic Transformation - 九州通 is focusing on a "three new and two modernization" strategy in 2024, achieving significant results in new products, new retail, new medical services, digitalization, and real estate securitization [2]. - The company has established a multi-level real estate equity capital operation platform, marking its transition from heavy assets to light assets [3]. Group 2: Financial Performance - In 2024, 九州通's total revenue reached 151.81 billion yuan, a year-on-year increase of 2.58%, while net profit attributable to shareholders was 2.507 billion yuan, up 39.88% [2]. - In Q1 2025, the company reported revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, reflecting an 80.38% growth [2]. Group 3: Product Pipeline Expansion - 九州通's product pipeline is expanding with the approval of "Betamethasone Sodium Phosphate Injection," which is expected to enhance market share and strengthen the company's competitive position in the injection product market [1][4]. - The company achieved sales revenue of 3.007 billion yuan from its self-produced and OEM pharmaceutical business in 2024, marking a 21.49% increase [5]. Group 4: Research and Development - 九州通's R&D investment in 2024 was 346 million yuan, reflecting a year-on-year growth of 24.32% [2].

Core Viewpoint - The company, Sely Medical, is undergoing significant changes in its funding strategy, including the termination of a specific investment project and the reallocation of remaining funds to enhance liquidity [1][2][3]. Group 1: Company Financials - As of June 6, 2025, Sely Medical's stock closed at 12.18 yuan, down 2.87% from the previous week [1]. - The company's total market capitalization is 2.327 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4723rd in the A-share market [1]. Group 2: Fundraising and Project Updates - The company has fully repaid all funds raised for temporary liquidity support from its 2018 non-public A-share issuance [3]. - Sely Medical plans to terminate the "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" from its 2018 fundraising, reallocating the remaining 17253.61 million yuan to permanent liquidity support [2][3]. - The decision to terminate the project is attributed to changes in IVD industry policies, market environment shifts, and necessary strategic adjustments by the company [2]. Group 3: Upcoming Events - Sely Medical will hold its third extraordinary general meeting of shareholders on June 20, 2025, to review the proposal regarding the termination of the investment project and the reallocation of funds [2][3].

Core Viewpoint - The document outlines the management system for subsidiaries of Zhejiang Zhenyuan Co., Ltd., emphasizing the need for orderly, standardized, and efficient operations while controlling investment risks and protecting the rights of the company and its investors [1]. Group 1: General Principles - The management of subsidiaries follows principles of strategic unity and collaborative development, ensuring that subsidiary strategies align with the overall company strategy [2]. - Subsidiaries maintain independent daily operations, allowing them to establish their internal management structures while ensuring compliance with regulatory requirements [2]. - Major transactions or matters that could significantly impact the company or subsidiaries require decision-making and approval from the company [2]. Group 2: Corporate Governance - Subsidiaries must establish governance structures and internal management systems in accordance with relevant laws and regulations [3]. - Subsidiaries are required to hold shareholder meetings and board meetings as per legal requirements, with specific timelines for annual meetings [4]. - Major transactions must be reviewed and approved by the subsidiary's board or shareholders, especially those involving significant investments or contracts [4][5]. Group 3: Personnel and Assessment Management - The company appoints or recommends directors, supervisors, and senior management for subsidiaries, ensuring compliance with subsidiary charters [6]. - A performance assessment mechanism is established for subsidiaries, linking responsibilities and rewards to the performance of subsidiary leaders [7]. - Any failure by subsidiary management to fulfill their responsibilities may lead to disciplinary actions and potential legal liabilities [7]. Group 4: Financial Management - Subsidiaries must adhere to a unified accounting system and establish financial management practices in line with company policies [8]. - The company’s financial management department oversees subsidiary financial activities, including budget preparation and financial reporting [8]. - Subsidiaries are prohibited from applying for bank credit without company approval, ensuring centralized financial control [8][9]. Group 5: Business Control - The company guides subsidiaries in formulating annual business plans and budgets, which must be approved by the company [9]. - Subsidiaries are not allowed to provide external guarantees or donations without prior approval from the company [9][10]. - Any significant transactions outside the approved scope may result in penalties for responsible parties [10]. Group 6: Audit Supervision - The company conducts regular audits of subsidiaries to ensure compliance with laws and internal regulations [11]. - Audits cover various aspects, including legal compliance, management practices, and financial performance [11]. - Subsidiaries must cooperate with audits and provide necessary documentation [11]. Group 7: Information Reporting and Disclosure Management - Subsidiaries must comply with information disclosure regulations and maintain confidentiality of undisclosed information [12]. - Designated personnel are responsible for communication between the company and subsidiaries regarding information management [12]. - Accurate and complete reporting of information is mandatory, with strict penalties for any misrepresentation [12][13]. Group 8: Supplementary Provisions - The company’s relevant departments are tasked with refining management details and processes based on the established system [13]. - Any matters not covered by the system will be governed by applicable laws and company regulations [13]. - The board of directors is responsible for interpreting and amending the management system [13].